leadf
logo-loader
viewAnteris Technologies Ltd

Admedus heads to market, granted trading halt

au_admedus_manufacturing_facility_3_358.jpg

Admedus (ASX:AHZ) has made strong progress with its lead regenerative tissue product CardioCel® receiving initial orders in Hong Kong and expanding its footprint in France and Italy.

The company has now been granted an ASX trading halt in relation to a capital raising.

The halt will last until the earlier of the announcement being made or the start of trade on 18th March 2015.

CardioCel® is now used in over 60 centres globally with 28 in Europe and a further 28 centres in the U.S.
 
Over 1,200 patients have benefited from CardioCel® as part of their cardiovascular repair surgery.

It is also on track for its strongest sales quarter.



Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: Anteris Technologies Ltd

Price: 3.99 AUD

ASX:AVR
Market: ASX
Market Cap: $23.58 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Anteris Technologies Ltd named herein, including the promotion by the Company of Anteris Technologies Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Admedus CEO in New York to update on recent key milestones

Admedus Ltd (ASX:AHZ) CEO Wayne Paterson visited the Proactive Investors New York studio to update on key milestones the company has achieved in the past few months, including receiving European approval on two of its products.

on 03/17/2019

2 min read